Phillip A Thompson
33PUBLICATIONS
154CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (33)
Sort by Publication Date:
|Mar 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.Alexandre Bazinet, Alessandra Ferrajoli, Nitin Jain
|Mar 17, 2026
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.Mathias Castonguay, Mary Ann Anderson, Philip A Thompson
|Feb 12, 2026
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson
|Jan 07, 2026
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.Gloria Iacoboni, Emil Ramsø Kyvsgaard, Víctor Navarro Garcés
|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.Sasanka M Handunnetti, Amit Khot, Piers Blombery
|Jul 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.Stephen P Mulligan, Philip A Thompson, Joel Wight
Pageof 6
Frequent Collaborators
7 joint publications
Jan Burger
7 joint publications
William Wierda
6 joint publications
Tapan M Kadia
6 joint publications
Prithviraj Bose
5 joint publications
John F Seymour
4 joint publications
Naveen Pemmaraju
4 joint publications
Naval G Daver
4 joint publications
Christine B Peterson
4 joint publications
Constantine Tam
4 joint publications
Erin Parry
